A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis

• Status: Active, not recruiting
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of ANB019 in subjects with Palmoplantar Pustulosis (PPP)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AnaptysBio, Inc.

Criteria

Inclusion Criteria:

• Clinically confirmed diagnosis of PPP

• Disease duration of at least 6 months prior to screening

• Present with active pustules on palms or/and soles at screening

Exclusion Criteria:

• Any other ongoing inflammatory disease that interfere with the investigator's ability to evaluate the subject's response to therapy

• History of recurrent or active/serious infection

• Ongoing use of psoriasis prohibited medication

Other protocol-defined inclusion/exclusion criteria may apply